Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Quantifying the potential for dominant spread of SARS-CoV-2 variant B.1.351 in the United States

View ORCID ProfilePratha Sah, Thomas N. Vilches, Affan Shoukat, Abhishek Pandey, Meagan C. Fitzpatrick, Seyed M. Moghadas, Alison P. Galvani
doi: https://doi.org/10.1101/2021.05.10.21256996
Pratha Sah
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pratha Sah
Thomas N. Vilches
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
2Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Affan Shoukat
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abhishek Pandey
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meagan C. Fitzpatrick
3Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W Baltimore St, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seyed M. Moghadas
2Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison P. Galvani
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alison.galvani@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Recent evidence suggests that the SARS-CoV-2 variant B.1.351 exhibits partial immune evasion to antibodies generated by natural infection or vaccination. We used a dynamic transmission model to evaluate whether this variant could become dominant in the United States given mounting vaccination coverage and other circulating variants. We show that B.1.351 is unlikely to become dominant even when all fully vaccinated individuals return to their pre- pandemic behavior. However, an improved selection advantage of B.1.351 arising from a combination of increased transmission and immune escape could drive this variant to dominance as early as July 2021 and fuel a resurgence of cases and hospitalizations. Our study underscores the urgency for continued rollout of the current generation of vaccines despite the emergence of immune escape variants.

One-Sentence Summary Within the range of early estimates for its immune evasion and transmissibility, the B.1.351 variant is unlikely to spread widely in the United States.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

APG acknowledges funding from NSF Expeditions grant 1918784, NIH grant 1R01AI151176-01, NSF grant RAPID-2027755 and the Notsew Orm Sands Foundation. SMM was supported by the Canadian Institutes of Health Research [OV4 - 170643, COVID-19 Rapid Research] and Natural Sciences and Engineering Research Council of Canada, NSERC EIDM grant.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was not required as all data is publicly available.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are available in the main text or the supplementary materials. The simulation codes are available at: https://github.com/thomasvilches/Third_strain

https://github.com/thomasvilches/Third_strain

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Quantifying the potential for dominant spread of SARS-CoV-2 variant B.1.351 in the United States
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Quantifying the potential for dominant spread of SARS-CoV-2 variant B.1.351 in the United States
Pratha Sah, Thomas N. Vilches, Affan Shoukat, Abhishek Pandey, Meagan C. Fitzpatrick, Seyed M. Moghadas, Alison P. Galvani
medRxiv 2021.05.10.21256996; doi: https://doi.org/10.1101/2021.05.10.21256996
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Quantifying the potential for dominant spread of SARS-CoV-2 variant B.1.351 in the United States
Pratha Sah, Thomas N. Vilches, Affan Shoukat, Abhishek Pandey, Meagan C. Fitzpatrick, Seyed M. Moghadas, Alison P. Galvani
medRxiv 2021.05.10.21256996; doi: https://doi.org/10.1101/2021.05.10.21256996

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (171)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8794)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (396)
  • Infectious Diseases (except HIV/AIDS) (10575)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1762)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3992)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)